600521 Zhejiang Huahai Pharmaceutical
- 16.40
- +0.01+0.06%
Zhejiang Huahai Pharmaceutical News
Express News | Zhejiang Huahai Pharmaceutical: publicly listing the transfer of the new antidepressant drug, hydrochloride hydroxypiperidone tablets, innovative research and development achievements.
Express News | Zhejiang Huahai Pharmaceutical: Listed for transfer of the HHT101 project patent rights and technological achievements.
Zhejiang Huahai Pharmaceutical (600521.SH): Clinical trial applications for HB0028 injection and HB002.1T injection have been approved.
Zhejiang Huahai Pharmaceutical (600521.SH) released an announcement, stating that the company's holding subsidiary Shanghai Huadao Tai Biopharmaceutical Co., Ltd...
Express News | Zhejiang Huahai Pharmaceutical: Subsidiary obtains drug clinical trial license.
GF Securities Starts Zhejiang Huahai Pharmaceutical at Buy With 21.57 Yuan Price Target
Express News | GF SEC has resumed following Zhejiang Huahai Pharmaceutical, rating it as a buy with a Target Price of 21.57 yuan.
Express News | Zhejiang Huahai Pharmaceutical: The holding subsidiary Huao Tai plans to increase its capital and introduce investors.
Zhejiang Huahai Pharmaceutical (600521): The integration of Active Pharmaceutical Ingredient and formulation is a leading player, with its Global layout accelerating.
Investment highlights: The Active Pharmaceutical Ingredient Industry is at the upward phase of its cycle, and under multiple catalysts, long-term growth potential is expected to be unlocked. In 2023, the domestic Active Pharmaceutical Ingredient industry experienced high baselines due to orders related to the pandemic in 2022, as well as downstream formulation manufacturers digesting stock accumulated during the pandemic.
Chinese Drug Regulator Accepts Huahai Pharma Unit's Application for Adalimumab Injection
Huahai Pharmaceutical's Two Drugs Secures Spot in China's National Drug Procurement Program
Express News | The opening of the tenth batch of national Pharmaceutical centralized purchasing has prompted nearly 30 listed companies to announce their products are likely to be selected after the market close.
Zhejiang Huahai Pharmaceutical (600521.SH): Products are expected to be selected for the tenth batch of national pharmaceutical centralized procurement.
On December 13, Gelonghui reported that Zhejiang Huahai Pharmaceutical (600521.SH) announced that on December 12, 2024, the company participated in the bidding for the 10th batch of national drug centralized procurement organized by the National Joint Procurement Office, and the company products Apsaglerone Tablets and Sitagliptin Metformin Tablets (II) are expected to be selected for this centralized procurement.
Express News | Zhejiang Huahai Pharmaceutical: The subsidiary's application for上市许可for the pharmaceutical Adalimumab injection has been accepted.
Express News | The latest bid price for Sitagliptin tablets in collective procurement has dropped to below 0.2 yuan per tablet, a decline of over 90%.
Zhejiang Huahai Pharmaceutical Gets China Nod for Type 2 Diabetes Drug
Huahai Pharmaceutical Gets Nod to Register Dapagliflozin Tablets
Express News | Zhejiang Huahai Pharmaceutical: The first subject in New Zealand to be dosed with the TSLP/IL-11 bispecific monoclonal antibody independently developed by its subsidiary.
Research reports focus | China Merchants Securities: zhejiang huahai pharmaceutical Q3 profit ability significantly improved, maintaining a "strong recommendation" rating
China Merchants Research Reports pointed out that Zhejiang Huahai Pharmaceutical (600521.SH) Q3 overall performance is close to the upper limit of the forecast, with significantly improved profitability. It is expected that the company's active pharmaceutical ingredient and formulation product structure will continue to adjust, the proportion of new products will increase, and the manifestation of lean management, economies of scale, and the effectiveness of technological transformation will drive a significant increase in profit margin. Since the beginning of this year, several of the company's products have entered key clinical stages. Zhejiang Huahai Pharmaceutical is a leading domestic integrated company in active pharmaceutical ingredients and formulations, with the turning point for active pharmaceutical ingredients and generic drug formulations trending upward, the profitability is expected to continue to improve. Innovative drugs are gradually entering the harvest period, and innovative assets are exp
Zhejiang Huahai Pharmaceutical Gets China Nod for Anti-Tumor Injection
Zhejiang Huahai Pharmaceutical (600521): Performance close to the upper limit of the forecast, highlighting the resilience of the industry leader.
In the first three quarters of 2024, zhejiang huahai pharmaceutical achieved a revenue of 7.248 billion yuan, an increase of 16.76% year-on-year; net income attributable to shareholders was 1.031 billion yuan, an increase of 42.92% year-on-year; net income attributable to shareholders after deducting non-recurring gains and losses was 1.033 billion yuan, an increase of +.
No Data
